Florian Moik

Florian Moik

Medizinische Universität Wien

H-index: 18

Europe-Austria

About Florian Moik

Florian Moik, With an exceptional h-index of 18 and a recent h-index of 18 (since 2020), a distinguished researcher at Medizinische Universität Wien, specializes in the field of Oncology, Haemostasis, Internal Medicine.

His recent articles reflect a diverse array of research interests and contributions to the field:

Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view

Incidence and outcomes of bleeding events in patients with cancer: results from a prospective cohort study

Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies

Growth differentiation factor-15 is associated with bleeding risk in patients with cancer: results from a prospective cohort

Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the …

VTE with Amivantamab plus Chemotherapy in NSCLC.

Thrombosis rates in patients with cancer receiving immune checkpoint inhibitors: results from a prospective cohort study

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Florian Moik Information

University

Position

___

Citations(all)

1864

Citations(since 2020)

1853

Cited By

161

hIndex(all)

18

hIndex(since 2020)

18

i10Index(all)

29

i10Index(since 2020)

29

Email

University Profile Page

Medizinische Universität Wien

Google Scholar

View Google Scholar Profile

Florian Moik Skills & Research Interests

Oncology

Haemostasis

Internal Medicine

Top articles of Florian Moik

Title

Journal

Author(s)

Publication Date

Molecular diagnostics tailoring personalized cancer therapy—an oncologist’s view

Jakob M Riedl

Florian Moik

Tamara Esterl

Sarah M Kostmann

Armin Gerger

...

2024/2

Incidence and outcomes of bleeding events in patients with cancer: results from a prospective cohort study

Hämostaseologie

C Englisch

F Moik

D Steiner

A Berghoff

M Preusser

...

2024/2

Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies

Florian Moik

Jakob M Riedl

Cornelia Englisch

Cihan Ay

2024/1/8

Growth differentiation factor-15 is associated with bleeding risk in patients with cancer: results from a prospective cohort

European Heart Journal

B Allen

B Mumma

N Tran

R Christenson

RG Wilkerson

...

2023/11

Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the …

Annals of Oncology

F Moik

JM Riedl

C Ay

2024

VTE with Amivantamab plus Chemotherapy in NSCLC.

The New England Journal of Medicine

Florian Moik

Jakob M Riedl

Cihan Ay

2024/2/1

Thrombosis rates in patients with cancer receiving immune checkpoint inhibitors: results from a prospective cohort study

Hämostaseologie

C Englisch

F Moik

D Steiner

A Starzer

A Berghoff

...

2024/2

Cardiovascular biomarkers for the prediction of adverse cardiovascular events and mortality in patients with cancer

Hämostaseologie

F Moik

S Kraler

F Montecucco

L Liberale

S Nopp

...

2023/2

Atrial fibrillation and cancer: prevalence and relative risk from a nationwide study

Research and Practice in Thrombosis and Haemostasis

Cihan Ay

Ella Grilz

Stephan Nopp

Florian Moik

Oliver Königsbrügge

...

2023/1/1

OC 46.4 Association of Growth Differentiation Factor-15 (GDF-15) with Thromboembolism and Mortality in Patients with Cancer: Findings from the Vienna Cats Study

Research and Practice in Thrombosis and Haemostasis

S Nopp

F Moik

S Kraler

C Englisch

M Preusser

...

2023/10/1

Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study

Journal of Thrombosis and Haemostasis

Stephan Nopp

Florian Moik

Simon Kraler

Cornelia Englisch

Matthias Preusser

...

2023/9/1

Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer

Hämostaseologie

Cornelia Englisch

Florian Moik

Johannes Thaler

Silvia Koder

M Preusser

...

2023/2

Early kinetics of C reactive protein for cancer-agnostic prediction of therapy response and mortality in patients treated with immune checkpoint inhibitors: a multicenter …

Journal for Immunotherapy of Cancer

Dominik A Barth

Florian Moik

Sarah Steinlechner

Florian Posch

Marie-Christina Mayer

...

2023

Neutrophils in lung cancer patients: Activation potential and neutrophil extracellular trap formation

Research and Practice in Thrombosis and Haemostasis

Lisa-Marie Mauracher

Lena Hell

Florian Moik

Moritz Krall

Cornelia Englisch

...

2023/2/1

1844MO Association of peripheral blood leukocyte DNA methylation profiles with the development of depressive symptoms in lung cancer patients undergoing systemic therapy

Annals of Oncology

AM Starzer

JH Fuerst

E Tomasich

L Gottmann

JM Berger

...

2023/10/1

Pharmacokinetic-guided versus standard prophylaxis in hemophilia-A systematic review and meta-analysis

Daniel Kraemmer

Oliver Königsbrügge

Florian Moik

Brigitte Wildner

Cihan Ay

...

2023/9/20

OC 46.5 Tissue Factor Pathway Inhibitor is Associated with Risk of Venous Thromboembolism and All-Cause Mortality in Patients with Cancer

Research and Practice in Thrombosis and Haemostasis

C Englisch

F Moik

J Thaler

S Koder

M Preusser

...

2023/10/1

Early CRP kinetics after initiation of immune checkpoint inhibitors is a predictive biomarker for treatment response independent of the tumor antity [Poster]

JM Riedl

D Barth

S Steinlechner

F Moik

F Posch

...

2022

Venous and arterial thromboembolism in patients with cancer treated with targeted anti-cancer therapies

Florian Moik

Cihan Ay

2022/5/1

Unanswered questions in cancer‐associated thrombosis

Kristen M Sanfilippo

Florian Moik

Matteo Candeloro

Cihan Ay

Marcello Di Nisio

...

2022/9

See List of Professors in Florian Moik University(Medizinische Universität Wien)